BR9502707A - Composto composição farmacêutica e método para o tratamento de uma afecção - Google Patents

Composto composição farmacêutica e método para o tratamento de uma afecção

Info

Publication number
BR9502707A
BR9502707A BR9502707A BR9502707A BR9502707A BR 9502707 A BR9502707 A BR 9502707A BR 9502707 A BR9502707 A BR 9502707A BR 9502707 A BR9502707 A BR 9502707A BR 9502707 A BR9502707 A BR 9502707A
Authority
BR
Brazil
Prior art keywords
treating
condition
pharmaceutical composition
compound pharmaceutical
compound
Prior art date
Application number
BR9502707A
Other languages
English (en)
Inventor
Yuhpyng L Chen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR9502707A publication Critical patent/BR9502707A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
BR9502707A 1994-06-16 1995-06-07 Composto composição farmacêutica e método para o tratamento de uma afecção BR9502707A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26005594A 1994-06-16 1994-06-16

Publications (1)

Publication Number Publication Date
BR9502707A true BR9502707A (pt) 1996-06-04

Family

ID=22987613

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9502707A BR9502707A (pt) 1994-06-16 1995-06-07 Composto composição farmacêutica e método para o tratamento de uma afecção

Country Status (27)

Country Link
US (1) US6248753B1 (pt)
EP (1) EP0765327B1 (pt)
JP (1) JP2891544B2 (pt)
KR (1) KR100235277B1 (pt)
CN (1) CN1056611C (pt)
AT (1) ATE182332T1 (pt)
AU (1) AU687196B2 (pt)
BR (1) BR9502707A (pt)
CA (1) CA2192820C (pt)
CO (1) CO4290424A1 (pt)
CZ (1) CZ287613B6 (pt)
DE (1) DE69510940T2 (pt)
DK (1) DK0765327T3 (pt)
ES (1) ES2135062T3 (pt)
FI (1) FI112659B (pt)
GR (1) GR3031166T3 (pt)
HU (1) HU219911B (pt)
IL (1) IL114003A (pt)
MX (1) MX9606504A (pt)
NO (1) NO307968B1 (pt)
NZ (1) NZ284846A (pt)
PE (1) PE13396A1 (pt)
PL (1) PL181895B1 (pt)
RU (1) RU2135498C1 (pt)
TW (1) TW432064B (pt)
WO (1) WO1995034563A1 (pt)
ZA (1) ZA954679B (pt)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US7125880B1 (en) 1995-06-06 2006-10-24 Pfizer Inc. Corticotropin releasing factor antagonists
AU738304B2 (en) * 1995-10-13 2001-09-13 Neurogen Corporation Certain pyrrolopyridine derivatives; novel CRF 1 specific ligands
US6992188B1 (en) 1995-12-08 2006-01-31 Pfizer, Inc. Substituted heterocyclic derivatives
EP0901476A4 (en) * 1996-03-26 2001-08-16 Du Pont Pharm Co PYRIDINES AND PYRIMIDINES FUSION ARYLOXY AND ARYLTHIO AND DERIVATIVES THEREOF
ZA971896B (en) 1996-03-26 1998-09-07 Du Pont Merck Pharma Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives
US6107300A (en) * 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
ZA972497B (en) 1996-03-27 1998-09-25 Du Pont Merck Pharma Arylamino fused pyridines and pyrimidines
ZA973884B (en) 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
US7094782B1 (en) 1996-07-24 2006-08-22 Bristol-Myers Squibb Company Azolo triazines and pyrimidines
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US6124289A (en) * 1996-07-24 2000-09-26 Dupont Pharmaceuticals Co. Azolo triazines and pyrimidines
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
NZ333727A (en) * 1996-08-06 2000-09-29 Pfizer Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic arylsulfonylamino hydroxamic acid derivatives
TW477787B (en) * 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
CA2265672C (en) * 1996-09-16 2008-12-02 Du Pont Pharmaceuticals Company Pyrazinones and triazinones and their derivatives thereof
CA2281525A1 (en) 1997-02-18 1998-08-20 Neurocrine Biosciences, Inc. Biazacyclic crf antagonists
TW589309B (en) * 1997-07-03 2004-06-01 Bristol Myers Squibb Pharma Co Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
WO1999011643A1 (en) * 1997-09-02 1999-03-11 Du Pont Pharmaceuticals Company Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
NL1010018C2 (nl) * 1997-09-09 1999-03-10 Duphar Int Res Chinoline en chinazoline derivaten met corticotropine releasing factor (CRF) antagonistische werking.
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
EP1068205A1 (en) 1998-04-02 2001-01-17 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-tetrahydro-9h pyrimidino 2,3-b]indole and 5,6,7,8-tetrahydro-9h-pyrimidino 4,5-b]indole derivatives: crf1 specific ligands
US6472402B1 (en) 1998-04-02 2002-10-29 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-Tetrahydro-9H-Pyridino [2,3-B]indole derivatives
JP2002510687A (ja) 1998-04-02 2002-04-09 ニューロゲン コーポレイション アミノアルキル置換ピロロ［２，３−ｂ］ピリジンおよびピロロ［２，３−ｄ］ピリミジン誘導体：ｃｒｆ１レセプタのモジュレータ
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
DE19837387A1 (de) * 1998-08-18 2000-02-24 Aventis Res & Tech Gmbh & Co 3'-Desoxypentopyranosyl-Nucleinsäure, ihre Herstellung und Verwendung
US6174912B1 (en) 1998-08-21 2001-01-16 Dupont Pharmaceuticals Company Nitrogen substituted imidazo[4,5-C]pyrazoles as corticotropin releasing hormone antagonists
CN1217945C (zh) * 1998-11-12 2005-09-07 纽罗克里恩生物科学有限公司 Crf受体拮抗剂以及与其有关的方法
US6531475B1 (en) 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
ATE240958T1 (de) * 1998-11-12 2003-06-15 Neurocrine Biosciences Inc Crf rezeptor-antagonisten und darauf bezogene methoden
US6271380B1 (en) 1998-12-30 2001-08-07 Dupont Pharmaceuticals Company 1H-imidazo[4,5-d]pyridazin-7-ones, 3H-imidazo-[4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands
EP1040831A3 (en) * 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
US6387894B1 (en) 1999-06-11 2002-05-14 Pfizer Inc. Use of CRF antagonists and renin-angiotensin system inhibitors
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
CZ20021086A3 (cs) 1999-09-30 2002-10-16 Neurogen Corporation Alkylendiaminem substituované heterocykly
CO5271670A1 (es) * 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
EP1244666A1 (en) 1999-12-17 2002-10-02 Bristol-Myers Squibb Pharma Company Imidazopyrimidinyl and imidazopyridinyl derivatives
KR20030016222A (ko) * 2000-02-14 2003-02-26 니뽄 다바코 산교 가부시키가이샤 수술후 스트레스 예방ㆍ치료제
EP1278749B1 (en) 2000-04-25 2005-01-26 Bristol-Myers Squibb Company USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO 3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS
US6630476B2 (en) 2000-07-07 2003-10-07 Bristol-Myers Squibb Pharma Company Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists
PE20020394A1 (es) * 2000-08-18 2002-06-21 Agouron Pharma Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2
DE10042093A1 (de) * 2000-08-26 2002-03-07 Dresden Arzneimittel Antikonvulsiv wirkende 6,7-Dihydro-pyrrolo[3,4-d]pyridin-5-one und Verfahren zu deren Darstellung
KR100860040B1 (ko) * 2000-09-22 2008-09-25 엔.브이.오가논 이환 헤테로방향족 화합물
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
DE10110747A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
US7091215B2 (en) 2001-04-27 2006-08-15 Eisai Co., Ltd. Pyrazolo[1,5-a]pyridines and medicines containing the same
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
GB0128287D0 (en) * 2001-11-26 2002-01-16 Smithkline Beecham Plc Novel method and compounds
PL371049A1 (en) * 2001-12-04 2005-06-13 F.Hoffmann-La Roche Ag Ring fused pyrazole derivatives
DE60331219D1 (de) * 2002-03-28 2010-03-25 Eisai R&D Man Co Ltd Azaindole als hemmstoffe von c-jun n-terminalen kinasen
GB0230045D0 (en) * 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
PL213633B1 (pl) 2002-10-22 2013-04-30 Eisai R&D Management Co Ltd Pochodne 7-fenylopirazolopirydyny, srodek terapeutyczny lub profilaktyczny i zastosowanie
US7176216B2 (en) 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
AR042667A1 (es) 2002-12-26 2005-06-29 Taisho Pharmaceutical Co Ltd Derivados de pirrolopirimidina y pirrolopiridina sustituidos con un grupo amino ciclico
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
DE102004042607A1 (de) 2004-09-03 2006-03-09 Bayer Healthcare Ag Substituierte Phenylaminothiazole und ihre Verwendung
US7652035B2 (en) 2004-10-19 2010-01-26 Neurocrine Bioscience, Inc. CRF receptor antagonists and methods relating thereto
EP1934219A1 (en) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
GB0525143D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525337D0 (en) * 2005-12-13 2006-01-18 Novartis Ag Organic compounds
JP2009529047A (ja) 2006-03-07 2009-08-13 アレイ バイオファーマ、インコーポレイテッド ヘテロ二環系ピラゾール化合物およびその使用
AU2007234408B2 (en) * 2006-04-04 2011-05-19 Fibrogen, Inc. Pyrrolo- and thiazolo-pyridine compounds as HIF modulators
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
DE102006042143A1 (de) 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
DE102006056739A1 (de) 2006-12-01 2008-06-05 Bayer Healthcare Ag Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung
DE102006056740A1 (de) 2006-12-01 2008-06-05 Bayer Healthcare Ag Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
DE102007035367A1 (de) 2007-07-27 2009-01-29 Bayer Healthcare Ag Substituierte Aryloxazole und ihre Verwendung
DE102007036076A1 (de) 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
DE102007061763A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituierte azabicyclische Verbindungen und ihre Verwendung
DE102007061764A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Anellierte Cyanopyridine und ihre Verwendung
DE102008013587A1 (de) 2008-03-11 2009-09-17 Bayer Schering Pharma Aktiengesellschaft Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung
WO2009128383A1 (ja) 2008-04-15 2009-10-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ３－フェニルピラゾロ［５，１－ｂ］チアゾール化合物
ES2428818T3 (es) 2008-05-29 2013-11-11 Bayer Intellectual Property Gmbh Dicianopiridinas sustituidas con 2-alcoxi y su uso
TW201020244A (en) 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
DE102008062567A1 (de) 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Dipeptoid-Prodrugs und ihre Verwendung
DE102009006602A1 (de) 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
DE102010030688A1 (de) 2010-06-30 2012-01-05 Bayer Schering Pharma Aktiengesellschaft Substituierte Dicyanopyridine und ihre Verwendung
US20120058983A1 (en) 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
WO2012158913A2 (en) 2011-05-17 2012-11-22 Discoverybiomed Inc. Treating protein folding disorders with small molecule cftr correctors
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP2922853A4 (en) 2012-11-20 2016-11-23 Discoverybiomed Inc SMALL MOLECULE BICYCLIC AND TRICYCLIC CFTR CORRECTING DEVICES
EP2922852A4 (en) * 2012-11-20 2016-05-25 Discoverybiomed Inc CFTR SMALL MOLECULE CORRECTIVES
MX2015009270A (es) 2013-01-18 2015-10-30 Hoffmann La Roche Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk).
CN108558876B (zh) * 2018-05-28 2020-08-04 中南大学 吡唑[3,4-b]并吡啶类衍生物及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3925388A (en) * 1971-08-05 1975-12-09 Squibb & Sons Inc 4-Piperazino-{8 3,4-b{9 pyridine-5-carboxylic acids and esters
US3804843A (en) * 1971-12-23 1974-04-16 Squibb & Sons Inc Amino derivatives of pyrazolopyridine carbonitriles
DE3145287A1 (de) 1981-11-14 1983-05-19 Troponwerke GmbH & Co KG, 5000 Köln Pyrrolo (2.3-d)pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
IT1154024B (it) * 1982-09-22 1987-01-21 Lepetit Spa Derivati pridinici e procedimento per la loro produzione
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US5063245A (en) 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
JPH05196008A (ja) 1991-11-20 1993-08-06 Myotoku Kk 空気圧動作装置とその制御装置
WO1993010715A2 (en) 1991-12-03 1993-06-10 Vesitec Medical, Inc. Surgical treatment of stress urinary incontinence
IT222061Z2 (it) 1991-12-03 1994-12-29 Hydro Aluminium Systems Spa Complesso di profilati metallici per serramenti muniti di squadrette di rinforzo
JPH0669494B2 (ja) 1991-12-04 1994-09-07 南雄 河野 医療用窓付断熱カテーテル
KR19990067704A (ko) * 1992-12-17 1999-08-25 디. 제이. 우드, 스피겔 알렌 제이 부신피질자극호르몬 유리인자 길항제로서의 피롤로피리미딘을함유하는 약학 조성물
TW444018B (en) * 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
CN1142817A (zh) 1993-10-12 1997-02-12 杜邦麦克制药有限公司 1n-烷基-n-芳基嘧啶胺及其衍生物

Also Published As

Publication number Publication date
EP0765327B1 (en) 1999-07-21
HUT75776A (en) 1997-05-28
NZ284846A (en) 1998-12-23
PL317705A1 (en) 1997-04-28
GR3031166T3 (en) 1999-12-31
CZ287613B6 (en) 2001-01-17
TW432064B (en) 2001-05-01
KR100235277B1 (ko) 1999-12-15
PE13396A1 (es) 1996-04-27
EP0765327A1 (en) 1997-04-02
JPH09507855A (ja) 1997-08-12
NO965378D0 (no) 1996-12-13
US6248753B1 (en) 2001-06-19
CZ367096A3 (en) 1997-10-15
FI112659B (fi) 2003-12-31
NO965378L (no) 1996-12-13
CN1056611C (zh) 2000-09-20
DE69510940T2 (de) 1999-11-11
RU2135498C1 (ru) 1999-08-27
ES2135062T3 (es) 1999-10-16
WO1995034563A1 (en) 1995-12-21
MX9606504A (es) 1997-03-29
NO307968B1 (no) 2000-06-26
IL114003A (en) 1999-12-31
IL114003A0 (en) 1995-10-31
HU219911B (hu) 2001-09-28
PL181895B1 (pl) 2001-10-31
DK0765327T3 (da) 1999-11-29
AU2350595A (en) 1996-01-05
JP2891544B2 (ja) 1999-05-17
CA2192820C (en) 2000-11-28
FI965022A0 (fi) 1996-12-13
CA2192820A1 (en) 1995-12-21
HU9603469D0 (en) 1997-02-28
ATE182332T1 (de) 1999-08-15
CN1150803A (zh) 1997-05-28
AU687196B2 (en) 1998-02-19
DE69510940D1 (de) 1999-08-26
FI965022A (fi) 1996-12-13
ZA954679B (en) 1996-12-09
CO4290424A1 (es) 1996-04-17

Similar Documents

Publication Publication Date Title
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
ATE179610T1 (de) Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten
DK0915898T3 (da) Krystalform I af clarithromycin
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
BR9708114A (pt) Análogos xantona para o tratamento de doenças infecciosas.
FI972308A (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE199321T1 (de) Anti idiotypische antikörper gegen gonococcen und diese verwendende verfahren und zusammensetzungen.
DE59914712D1 (de) Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden
TR200100637T2 (tr) Yeni doğal ürün türevleri
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
DE69429856D1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
DE69913380D1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen
ATE453386T1 (de) Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten
ES2190581T3 (es) 2-aminotetralina opticamente activa, procedimiento para su preparacion y composiciones farmaceuticas que la contienen, activa en la prevencion y tratamiento de shock septico.
DE69737088D1 (de) Therapeutisches agens zur behandlung von fiv infektionen
PT907737E (pt) Muteina da il-6
PT1077694E (pt) Produtos terapeuticos de arilnitrona para o tratamento da doenca inflamatoria dointestino
DE60313344D1 (de) Verwendung von 4-pyridylmethyl-phthalazin-derivaten zur herstellung eines medikaments zur behandlung von myelodysplastischen syndromen

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
HJEG Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09W Correction of the decision to grant [chapter 9.1.4 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B24C Patent annual fee: request for for restoration

Free format text: REFERENTE A 14A E 15A ANUIDADES.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE AO NAO CUMPRIMENTO DO DESPACHO 24.3 NA RPI 2054 DE 18/05/2010 E COMPROVAR RECOLHIMENTO DA 16A, 17A E 18A ANUIDADES.